AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02396082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND-S Intervention
Description: MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
Study NCT02396082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Augmented Usual Care
Description: Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
Study NCT03082235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: gelatin capsules
Study NCT03082235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsules
Study NCT02221219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
Study NCT02221219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
Study NCT02221219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delay in umbilical cord clamp at birth
Description: provision of a \~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
Study NCT02221219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo infusion
Description: saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
Study NCT02221219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
Study NCT02221219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate cord clamp at birth
Description: no delay in umbilical cord clamp; \<10sec (recorded in delivery note)
Study NCT02221219 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: immediate cord clamp at birth
Description: no delay in umbilical cord clamp; \<10sec (recorded in delivery note)
Study NCT03007836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-activity natural killer
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study NCT00326924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: PRBC blood transfusions.
Study NCT00774436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focal cryotherapy
Description: Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
Study NCT04009642 — intervention group
Intervention type: OTHER
Intervention: Surely observational based on disease state
Description: Metabolism in T2DM vs non diabetic
Study NCT01418118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
Study NCT01360827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Description: 3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
Study NCT01418118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
Study NCT01418118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
Study NCT01418118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopexamine
Description: Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
Study NCT03954015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast Enhanced imaging
Description: Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
Study NCT03954015 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lumason
Description: FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
Study NCT03973684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tongue scraper group
Description: Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
Study NCT03870048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
Study NCT03973684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tongue scraper group
Description: Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
Study NCT01413984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping Women Recover/Beyond Trauma
Description: Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
Study NCT04476992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide-Sessions
Description: Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).
Study NCT04476992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide-Continuous and Sessions
Description: Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm.
Study NCT04597255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holographic optical coherence tomography
Description: Descriptive wavefront analysis with holographic optical coherence tomography
Study NCT01209546 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
Study NCT00315705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Study NCT00315705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Study NCT00315705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Study NCT02520778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO
Study NCT02520778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT02628535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD009
Description: B7-H3 x CD3 DART protein
Study NCT00892047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine XR plus aripiprazole
Description: Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
Study NCT00892047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine plus placebo
Description: Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
Study NCT03844932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ST-0529
Description: ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
Study NCT02446002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine + Naltrexone
Description: Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
Study NCT02157909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B sphere modified design contact lenses
Study NCT03844932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-0529
Description: ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
Study NCT01783431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
Study NCT01360827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Description: Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
Study NCT02157909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B sphere contact lenses
Study NCT01783431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
Study NCT03267017 — intervention group
Intervention type: OTHER
Intervention: posture changes
Description: Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
Study NCT01380665 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prevena Incisional Management System
Description: All evaluable patients will utilize the Prevena Incisional Management System
Study NCT02063308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oxaloacetate (OAA)
Study NCT01702077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Study NCT01209546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flutter group
Description: Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
Study NCT01209546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEP group
Description: Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
Study NCT01209546 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group Sham
Description: Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
Study NCT00437346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individualized and comprehensive information
Description: Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
Study NCT00437346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanzo Melt
Description: 30mg, od, 1/2 h before meal
Study NCT01702077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham feedback
Study NCT01345526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reconval K1 Cream
Study NCT01345526 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reconval Cream
Study NCT02393118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainPort V200 Device
Description: Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
Study NCT02116543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-6450
Study NCT02116543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01930045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (ISENTRESS™)
Description: Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
Study NCT01930045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAALOX (MAL)
Description: MAL (or generic equivalent) 20 mL oral single dose on Day 1
Study NCT02656758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive Executive function training
Description: Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
Study NCT02656758 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: intensive Executive function training
Description: Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
Study NCT04233359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic thoracoscopy
Description: Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
Study NCT04233359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided pleural biopsy
Description: In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
Study NCT04064320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lullaby intervention
Description: Listening to lullabies, and accompanied by lullabies touching their abdomen and think about their babies of hospitalized women with high-risk pregnancy
Study NCT03888391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TNS
Study NCT04313361 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No drug will be administered as part of this study.
Study NCT03790462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected.
Study NCT03247660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFM training
Description: See information included in arm/group descriptions.
Study NCT04397198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Speckle Tracking echocardiography
Description: Diagnostic tests:~Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.~MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.~Diagnostic tests:~Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers
Study NCT00829348 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: 60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
Study NCT03247660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HE
Description: See information included in arm/group descriptions.
Study NCT03247660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational strategy
Description: See information included in arm/group descriptions.